Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update

Artelo Biosciences, Inc. (NASDAQ:ARTL) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totaling 472,907 shares, an increase of 1,164.1% from the March 15th total of 37,410 shares. Approximately 72.6% of the company’s shares are sold short. Based on an average daily trading volume, of 13,584,198 shares, the short-interest ratio is presently 0.0 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Artelo Biosciences in a report on Friday, March 27th. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average price target of $54.00.

Artelo Biosciences Price Performance

Shares of Artelo Biosciences stock opened at $5.95 on Friday. The business has a 50-day moving average of $5.03 and a 200-day moving average of $6.67. The company has a market capitalization of $5.31 million, a PE ratio of -0.09 and a beta of 0.41. Artelo Biosciences has a 1-year low of $2.95 and a 1-year high of $85.80.

About Artelo Biosciences

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.